Roivant director sells 20K shares at ~$40
A Roivant Sciences director exercised 20,000 options and sold 20,000 shares under a Rule 10b5-1 trading plan at about five times the exercise price.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported an option exercise and same-day sale of common shares. On September 8, 2026, she exercised options for 20,000 shares at $8.80 per share, then sold 20,000 common shares at a weighted average price between $39.90 and $40.00 per share under a Rule 10b5-1 trading plan. Following the exercise, she held 18,578 stock options that remain exercisable until April 19, 2033.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Fitzgerald Meghan
Role
Director
Sold
20,000 shs ($798K)
Approx. gross sale proceeds
$798K
Approx. exercise cost
$176K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 20,000 | $0.00 | $0.00 |
| Exercise | Common Shares | 20,000 | $8.80 | $176K |
| Sale | Common Shares F1 | 20,000 | $39.90 | $798K |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,578 contracts (Direct);
Common Shares — 42,963 shares (Direct)
Footnotes (2)
- F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
- F2. Reflects an award of stock options to purchase Common Shares that is fully vested.
Key Figures
Options exercised: 20,000 options
Exercise price: $8.80 per share
Shares sold: 20,000 shares
+5 more
8 metrics
Options exercised
20,000 options
Stock options for common shares exercised on September 8, 2026
Exercise price
$8.80 per share
Price paid to exercise 20,000 stock options
Shares sold
20,000 shares
Common shares sold on September 8, 2026
Weighted average sale price
$39.90 per share
Weighted average price for 20,000 common shares sold, with trades from $39.90 to $40.00
Sale price range
$39.90–$40.00 per share
Range of individual trade prices for the 20,000 shares sold
Remaining stock options
18,578 options
Options held after the exercise reported in this filing
Option expiration date
April 19, 2033
Expiration date of the stock options involved in the exercise
Rule 10b5-1 plan adoption date
March 30, 2026
Date the trading plan governing the reported sales was adopted
Key Terms
weighted average price, Rule 10b5-1 trading plan, fully vested
3 terms
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 trading plan regulatory
"These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
fully vested financial
"Reflects an award of stock options to purchase Common Shares that is fully vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ROIV director Meghan Fitzgerald report on September 8, 2026?
She exercised 20,000 stock options for Roivant Sciences Ltd. common shares at $8.80 per share and then sold 20,000 common shares the same day at a weighted average price between $39.90 and $40.00 per share.
How many Roivant Sciences (ROIV) options did Meghan Fitzgerald exercise and at what price?
She exercised 20,000 stock options for Roivant Sciences Ltd. common shares at an exercise price of $8.80 per share, receiving 20,000 common shares in connection with that exercise.
How many Roivant Sciences (ROIV) stock options does Meghan Fitzgerald hold after the reported transactions?
After the September 8, 2026 option exercise, she holds 18,578 stock options for Roivant Sciences Ltd. common shares, and these options are reported to remain exercisable until April 19, 2033.
Are Meghan Fitzgerald’s reported Roivant Sciences (ROIV) options fully vested?
Yes. A footnote explains that the filing reflects an award of stock options to purchase Roivant Sciences Ltd. common shares that is fully vested, meaning they were fully exercisable at the time of the transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
